Kyverna Therapeutics, Inc. (KYTX) Stock Price & Analysis
Kyverna Therapeutics, Inc. (KYTX) rose 1.82% to USD 7.85 as of June 10, 2026 at 00:27 UTC, according to Nexqual real-time market data.
KYTX last closed at USD 7.71; the session ranged USD 7.62–7.95 on volume of 717,760 shares. Market capitalization is $477.24M, with a 52-week range of USD 2.52–13.67 (NMS). Source: Nexqual, June 10, 2026 at 00:27 UTC.
Key Statistics (as of June 10, 2026 at 00:27 UTC)
| Price | USD 7.85 |
|---|---|
| Change | ▲ 1.82% (up) |
| Previous Close | USD 7.71 |
| Open | USD 7.82 |
| Day Range | USD 7.62 – 7.95 |
| 52-Week Range | USD 2.52 – 13.67 |
| Volume | 717,760 shares |
| Market Cap | $477.24M |
| Exchange | NMS |
Technical Analysis (KYTX)
Nexqual's technical model rates KYTX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:27 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.48 (neutral) |
| vs SMA50 | Below (USD 9.02) |
| MACD | -0.41 (negative) |
Analyst Ratings (KYTX)
Wall Street analysts rate KYTX "Strong Buy" based on 5 analysts, with a mean price target of USD 30.4 (range USD 25–33), per Nexqual as of June 10, 2026 at 00:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 30.4 |
| High Target | USD 33 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (KYTX)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.68 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.8 vs est -0.86 ▲ beat |
| 2025-09-30 | USD -0.85 vs est -0.95 ▲ beat |
| 2025-06-30 | USD -0.97 vs est -1.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financials & Fundamentals (KYTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -74.55% |
| Debt / Equity | 17.26 |
| Current Ratio | 8.15 |
| Total Cash | $236.45M |
| Total Debt | $33.76M |
| Free Cash Flow | $-93.76M |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financial Health Score (KYTX)
Nexqual rates Kyverna Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $236M cash vs $34M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$150M |
| Efficiency | Critical — ROE -75%, ROA -39.5% |
Ownership (KYTX)
| Insider Ownership | +7.10% |
|---|---|
| Institutional Ownership | +74.05% |
| Shares Outstanding | 60.80M |
| Float | 35.50M |
| Short % of Float | +11.12% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Leadership (KYTX)
Kyverna Therapeutics, Inc. is led by Warner Biddle (age 58), CEO & Director, per Nexqual as of June 10, 2026 at 00:27 UTC.
| CEO & Director | Warner Biddle (age 58) |
|---|---|
| Chief Financial Officer | Gregory Martini (age 36) |
| Chief Technology Officer | Mayo Pujols (age 55) |
| Senior Vice President of Corporate Affairs | Tracy Rossin (age 48) |
Major Backers & Investors (KYTX)
Notable institutional backers of Kyverna Therapeutics, Inc. include GordonMD Global Investments LP, Gilead Sciences Inc, Bain Capital Life Sciences Investors, LLC, according to Nexqual as of June 10, 2026 at 00:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GordonMD Global Investments LP | 6.98% |
| Gilead Sciences Inc | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 5.12% |
| AIGH Capital Management LLC | 3.29% |
| Deerfield Management Company, L.P | 3.29% |
| Price (T.Rowe) Associates Inc | 2.56% |
| T. Rowe Price | 1.88% |
| Balyasny Asset Management LP | 1.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.8% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
From Kyverna Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
- Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
- The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
- It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | USD 21.15 | ▲ 15.83% |
| CGON | CG Oncology, Inc. | USD 56.67 | ▲ 5.49% |
| ARTV | Artiva Biotherapeutics, Inc. | USD 7.27 | ▲ 6.13% |
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
| JANX | Janux Therapeutics, Inc. | USD 13.62 | ▲ 1.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:27 UTC. This page is informational and not investment advice.